Thyroid Eye Disease

Ophthalmology·MeSH: Graves Ophthalmopathy

Prevalence

5581.4 / 100K

Incidence

918.7 / 100K/yr

18 drugs in development·10 companies·15 clinical trials

Drug Pipeline by Phase

Approved(1)

Drug	Company
tepezza	Horizon Therapeutics Public Ltd Co (HZNP)

Phase 3(8)

Drug	Company
Batoclimab	Immunovant, Inc. (IMVT)
elegrobart	Viridian Therapeutics, Inc.\DE (VRDN)
veligrotug	Viridian Therapeutics, Inc.\DE (VRDN)
VRDN-001	Viridian Therapeutics, Inc.\DE (VRDN)
VRDN-003	Viridian Therapeutics, Inc.\DE (VRDN)
VRDN-006	Viridian Therapeutics, Inc.\DE (VRDN)
VRDN-008	Viridian Therapeutics, Inc.\DE (VRDN)
zl-1109	Zai Lab Ltd (ZLAB)

Phase 2(3)

Phase 1(1)

Drug	Company
zb001	Zenas BioPharma, Inc. (ZBIO)

Preclinical(2)

Drug	Company
Anti-TSHR candidate	Viridian Therapeutics, Inc.\DE (VRDN)
TSHR Antagonist Program	Crinetics Pharmaceuticals, Inc. (CRNX)

Phase 1/Phase 2(3)

BioSniper tracks 18 drugs in development for Thyroid Eye Disease across 10 companies.

There are 15 clinical trials targeting Thyroid Eye Disease tracked by BioSniper.

The estimated prevalence of Thyroid Eye Disease is approximately 5581.4 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.